Glioblastoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AstraZeneca, Polaris Group, Crimson Biopharm, CNS Pharma, MimiVax, Berg, LLC, Ascletis, Denovo Bio

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Glioblastoma pipeline constitutes 195+ key companies continuously working towards developing 210+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Glioblastoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Glioblastoma Pipeline Report:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years.
• Glioblastoma companies working in the treatment market are J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, Ascletis Pharma, Oncotelic Therapeutics, Karyopharm Therapeutics, Philogen, AstraZeneca, Yumanity Therapeutics, and others, are developing therapies for the Glioblastoma treatment
• Emerging Glioblastoma therapies in the different phases of clinical trials are- JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, TVB2640, Trabedersen, Selinexor, Onfekafuspalfa, AZD1390, YTX7739, and others are expected to have a significant impact on the Glioblastoma market in the coming years.
• In October 2023, CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, is a first-in-class, oncolytic viral immunotherapy candidate being developed by Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to aid patients fight cancer.
• In October 2023, A novel dendritic cell vaccine known as DOC1021 was created by the immuno-oncology firm Diakonos Oncology Corp., which is in the clinical stages. The most prevalent and deadly malignant brain tumor in adults, glioblastoma multiforme (GBM), is the disease that the vaccination is designed to prevent. The life expectancy of the aggressive tumors is approximately 15 months after diagnosis. Approximately 7% of individuals who are diagnosed live for five years, but only 1% do so for ten years.
• Trabedersen, one of the new glioblastoma treatments, is in the Phase III of clinical development, while Selinexor is in the Phase II of studies.
• AZD1390 is a glioblastoma pipeline therapy that is now undergoing Phase I clinical studies.

Glioblastoma Overview
Glioblastoma (GBM), commonly known as a grade IV astrocytoma, is an aggressive brain tumor that grows quickly. Nearby brain tissue gets invaded, but it typically does not spread to distant organs. GBMs can develop from lower-grade astrocytomas or develop from new brain tumors.

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:
• JIN 001: J INTS BIO
• CT 179: Curtana Pharmaceuticals
• PRT3645: Prelude Therapeutics
• CD200AR L: OX2 Therapeutics
• ADI-PEG 20: Polaris Group
• CM93: Crimson Biopharm
• Berubicin: CNS Pharmaceuticals
• SurVaxM: MimiVax
• BPM31510: Berg, LLC
• ASC40: Ascletis
• Enzastaurin: Denovo Biopharma
• Marizomib: Celgene Corporation
• TVB2640: Ascletis Pharma
• Trabedersen: Oncotelic Therapeutics
• Selinexor: Karyopharm Therapeutics
• Onfekafuspalfa: Philogen
• AZD1390: AstraZeneca
• YTX7739: Yumanity Therapeutics

Glioblastoma Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Glioblastoma Molecule Type
Glioblastoma Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Glioblastoma Pipeline Therapeutics Assessment
• Glioblastoma Assessment by Product Type
• Glioblastoma By Stage and Product Type
• Glioblastoma Assessment by Route of Administration
• Glioblastoma By Stage and Route of Administration
• Glioblastoma Assessment by Molecule Type
• Glioblastoma by Stage and Molecule Type

DelveInsight's Glioblastoma Report covers around 210+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies at:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Glioblastoma Therapeutics Market include:
Key companies developing therapies for Glioblastoma are - Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, Philogen, Immatics N.V, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, and others.

Glioblastoma Pipeline Analysis:
The Glioblastoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
• Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Glioblastoma drugs and therapies-
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Glioblastoma Pipeline Market Drivers
• Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure• Demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.

Glioblastoma Pipeline Market Barriers
• However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.

Scope of Glioblastoma Pipeline Drug Insight
• Coverage: Global
• Key Glioblastoma Companies: J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, Ascletis Pharma, Oncotelic Therapeutics, Karyopharm Therapeutics, Philogen, AstraZeneca, Yumanity Therapeutics, and others
• Key Glioblastoma Therapies: JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, TVB2640, Trabedersen, Selinexor, Onfekafuspalfa, AZD1390, YTX7739, and others
• Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
• Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Glioblastoma Report Introduction
2. Glioblastoma Executive Summary
3. Glioblastoma Overview
4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment
5. Glioblastoma Pipeline Therapeutics
6. Glioblastoma Late Stage Products (Phase II/III)
7. Glioblastoma Mid Stage Products (Phase II)
8. Glioblastoma Early Stage Products (Phase I)
9. Glioblastoma Preclinical Stage Products
10. Glioblastoma Therapeutics Assessment
11. Glioblastoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Glioblastoma Key Companies
14. Glioblastoma Key Products
15. Glioblastoma Unmet Needs
16 . Glioblastoma Market Drivers and Barriers
17. Glioblastoma Future Perspectives and Conclusion
18. Glioblastoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Glioblastoma Market
https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Glioblastoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Glioblastoma Epidemiology
https://www.delveinsight.com/report-store/glioblastoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Glioblastoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Patient Monitoring Devices Market https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028.

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028.

Resorbable Vascular Scaffolds Market https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Protein Supplements Market
https://www.delveinsight.com/report-store/protein-supplements-market
Protein Supplements Market By Source (Animal-Based [Whey, Casein, Fish, Eggs, Others], Plant-Based [Soy, Rice, Pea, Spirulina, Others]), By Product Type (Protein Powders, Protein Bars, Ready-To-Drink, And Others), By Application (Sports Nutrition And Functional Foods), By Distribution Channel (Supermarkets And Hypermarkets, E-Commerce, Direct-To-Consumer, Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to the growing consumer awareness of having a protein rich diet,

Proteomics Market
https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Proteomics Market By Product & Services (Instrumentation Technology [Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, And Other], Reagents & Consumables, And Software & Services), By Application (Clinical Diagnostics, Drug Discovery, And Others), By End-User (Hospitals, Clinical Laboratories, Pharmaceutical Companies, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028.

Infrared Thermometer Market
https://www.delveinsight.com/report-store/infrared-thermometer-market
Infrared Thermometer Market By Product Type (Contact Thermometers And Non-Contact Thermometers), By End-User (Food And Beverage Industry, Electronic Industry, Healthcare Industry, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028 owing to the growing need for robust temperature measuring devices in critical industries and rise in the number of infectious diseases across the globe.

Hemoglobinopathies Market
https://www.delveinsight.com/report-store/sport-nutrition-market
Hemoglobinopathies Market By Indication (Thalassemia, Sickle Cell Anaemia, And Others), By Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2027 owing to the increasing prevalence of various hemoglobin disorders and the increasing research & developmental activities concerning to the hemoglobinopathies across the globe

Sport Nutrition Market
https://www.delveinsight.com/report-store/sport-nutrition-market
The Sports Nutrition Market By Product Type (Sports Drinks And Sports Supplements), By Distribution Channels (Hypermarkets & Supermarkets, E-Commerce, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing inclination toward following healthy and active lifestyle and growing importance of sports nutrition among athletes and sportspersons.

Endodontic Devices Market
https://www.delveinsight.com/report-store/endodontic-devices-market
Endodontic Devices Market By Product Type (Instruments [Apex Locators, Endodontic Motors, Endodontic Scalers, Endodontic Lasers, Handpieces, Machine-Assisted Obturation Systems, And Others], Consumables [Obturation, Access Cavity Preparation, Shaping And Cleaning]), By End-User (Dental Hospitals, Dental Clinics, And Others), and by geography is estimated to register growth at a remarkable CAGR during the forecast period from 2023-2028 owing to the rising patient pool associated with dental disorders, poor oral health, leading to increased number of root canal treatments, the increasing population opting for dental aesthetics, among others across the globe.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.